Value of vaccination
Published on: 09 October 2026 | 3 mins read | Publication size: 0.16 MB
Builds NHS resilience and helps cut waiting lists1

Value Of Vaccination 2026 0014 HospitalsVaccination has reduced the impact of RSV on hospitals. In 2024/25 there were:

50% fewer newborn RSV intensive care admissions2
30% fewer RSV admissions among 75-79s.3

Value Of Vaccination 2026 0013 Hospital AdmissionsFlu vaccination prevented around 100,000 hospital admissions in both 2024/25 and 2025/26. Higher uptake could ease pressure on primary care and hospitals.4,5

Value Of Vaccination 2026 0012 Health SystemVaccination is a cornerstone of a resilient and equitable health system.6

Value Of Vaccination 2026 0011 Value For MoneyVaccination programmes offer unparalleled value for money.7

Value Of Vaccination 2026 0010 SavingsThe NHS saves an estimated £400m annually from some vaccination programmes.7

One of the most powerful and effective public health interventions6

Value Of Vaccination 2026 0009 Pre SchoolPre-school vaccinations are estimated to prevent 4,960 deaths and 228,447 hospitalisations each year in England.8

Value Of Vaccination 2026 0008 HPV VaccinationHPV vaccination reduced recorded cervical cancer deaths to zero in women aged 20-24 between 2020 and 2024.9,10

Value Of Vaccination 2026 0007 Heart AttackPreventing flu or pneumonia cuts heart attack and stroke risk by 30–60% for people with pre-existing conditions.11

Value Of Vaccination 2026 0006 Antimicrobial Resistance1m+ people die from antimicrobial resistance (AMR) globally each year. Vaccines are crucial in tackling it.12

Value Of Vaccination 2026 0005 InfantsImmunisation has helped cut global infant deaths by 40% over the last 50 years.13

Supports productivity and economic growth

Value Of Vaccination 2026 0004 Powerful Economic StrategyVaccination is both a health imperative and a powerful economic strategy.14,15

Value Of Vaccination 2026 0003 Return On InvestmentAdult respiratory vaccination programmes deliver socio-economic benefits that far exceed their costs, with an up to 19.3x return on investment.16

Value Of Vaccination 2026 0002 Days Off SchoolSchool flu outbreaks cause 3.8 days off school for an ill child and 3.7 days off work for carers. Vaccination helps keep children in school.6,17

Value Of Vaccination 2026 0001 MeningitisMeningitis can cause permanent, life-changing after-effects. Vaccination can prevent some types.18,19

Value Of Vaccination 2026 0000 Lost ProductivityCOVID-19’s economic burden remains substantial, with lost productivity costs 7x higher than NHS costs.20

  1. Neri M, et al., ‘Vaccine-Preventable Hospitalisations from Seasonal Respiratory Diseases: What Is Their True Value?’, Vaccines, Vol 11, 5, 945, 2023, available at https://pubmed.ncbi.nlm.nih.gov/37243048.

  2. UK Health Security Agency, ‘Newborn ICU admissions drop 50% in first full year of RSV maternal vaccine programme’, accessed September 2026, available at https://www.gov.uk/government/news/rsv-maternal-vaccine-cuts-babyhospital-admissions-by-up-to-85.

  3. Mensah A et al., ‘Early impact of RSV vaccination in older adults in England’, The Lancet, Volume 405, Issue 10485, 2025, Pages 1139-1140, https://doi.org/10.1016/S0140-6736(25)00346-0.

  4. UK Health Security Agency, ‘Flu vaccine prevented around 100,000 hospital admissions’, accessed July 2026, available at https://www.gov.uk/government/news/flu-vaccine-prevented-around-100000-hospital-admissions.

  5. UK Health Security Agency, ‘Influenza in the UK, annual epidemiological report: winter 2025 to 2026’, accessed July 2026, available at https://www.gov.uk/government/statistics/influenza-in-the-uk-annual-epidemiological-report-winter-2025-to-2026/influenza-in-the-uk-annual-epidemiological-report-winter-2025-to-2026.

  6. Department of Health and Social Care, Department of Education, Medicines and Healthcare Products Regulatory Agency, NHS England and UK Health Security Agency, ‘Written Evidence (CVX0028) to House of Lords Childhood Vaccination Committee’, accessed July 2026, available at https://committees.parliament.uk/writtenevidence/166194/pdf.

  7. UK Health Security Agency, ‘UKHSA Advisory Board: Immunisation Schedule, May 2024’, accessed July 2026, available at https://www.gov.uk/government/publications/ukhsa-advisory-board-agenda.

  8. UK Health Security Agency, ‘Estimated annual deaths and hospitalisations prevented by routine childhood immunisation – England, 2026’, accessed July 2026, available at https://www.gov.uk/government/publications/routine-childhood-immunisation-deaths-and-hospitalisations-prevented/estimated-annual-deaths-and-hospitalisations-prevented-by-routine-childhood-immunisation-england-2026.

  9. Sasieni P and Falcaro M., ‘Cervical cancer mortality trends following HPV vaccination in England, 2001–24: an analysis of population-based mortality data’, The Lancet, accessed July 2026, available at https://doi.org/10.1016/S0140-6736(26)00918-9.

  10. Mahase E., ‘HPV jab: cervical cancer deaths fall to zero in vaccinated young women, research shows’, accessed August 2026, available at https://www.bmj.com/content/393/bmj-2026-100047.

  11. IFPMA and the Global Coalition on Aging, ‘Adult Immunization for Healthy Workforces and Healthy Economies in an Aging World: Infographic 2026’, accessed July 2026, available at https://www.ifpma.org/resources/adult-immunization-for-healthy-workforces-and-healthy-economies-in-an-aging-world.

  12. GBD 2021 Antimicrobial Resistance Collaborators, ‘Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050’, The Lancet, Vol 404, 10459, 1199 – 1226, 28 Sep 2024, available at https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01867-1/fulltext.

  13. Unicef, ‘Facts about vaccines: Why vaccines matter for children 2025’, accessed July 2026, available at https://www.unicef.org/stories/why-vaccines-matter-children.

  14. The Vaccine Alliance, ‘The economic impact of vaccination’, accessed July 2026, available at https://www.vaccinealliance.org/press/press_econ.

  15. UK Health Security Agency, ‘Immunisation Equity Strategy: Commitments for 2025 to 2035’, accessed July 2026, available at https://www.gov.uk/government/publications/ukhsa-immunisation-equity-strategy-commitments-for-2025-to-2030.

  16. Harrison, C. et al (2025), ‘The broader socio-economic value of adult respiratory disease vaccinations in the UK – results from a benefit cost analysis’, Expert Review of Vaccines, 24(1), 644–655, available at https://doi.org/10.1080/14760584.2025.2536093.

  17. Thorrington D, et al, ‘Social and economic impacts of school influenza outbreaks in England: survey of caregivers’, J Sch Health. 2017;87(3):209–216, available at https://pubmed.ncbi.nlm.nih.gov/28147460.

  18. Meningitis Now, ‘After-effects of meningitis’, accessed July 2026, available at https://www.meningitisnow.org/meningitis-explained/after-effects-meningitis.

  19. Meningitis Now, ‘What meningitis vaccines are available in the UK?’, accessed July 2026, available at https://www.meningitisnow.org/meningitis-explained/meningitis-vaccines.

  20. El Banhawi, H. et al, ‘The broader economic benefits of COVID-19 vaccination (2025) - Contract Research’, accessed July 2026, available from https://www.ohe.org/publications/the-broader-economic-benefits-of-covid-19-vaccination.

  • Publisher
    ABPI
  • Last reviewed date
    07 October 2026
  • Next review date
    07 October 2031